Workflow
蔗糖发酵物
icon
Search documents
圣达生物(603079) - 浙江圣达生物药业股份有限公司2025年第二季度主要经营数据公告
2025-08-25 11:01
证券代码:603079 证券简称:圣达生物 公告编号:2025-048 浙江圣达生物药业股份有限公司 2025年第二季度主要经营数据公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 二、报告期内主要产品销售地区分布基本情况 三、报告期内主要产品和原材料的价格变动情况 1、主要产品价格(不含税)变动情况 第二季度,公司主要产品维生素平均销售价格较上年同期上涨45.78%,环 单位:万元 主要产品 营业收入 (境内) 较上年同期 增减(%) 营业收入 (境外) 较上年同期 增减(%) 维生素 2,034.59 8.40 3,156.76 -28.87 生物保鲜剂及功 能配料 10,119.57 3.95 2,331.89 34.04 根据上海证券交易所《上市公司自律监管指引第3号行业信息披露:第十三 号——化工》(2022年修订)及《上市公司自律监管指引第3号行业信息披露: 第十四号——食品制造》(2022年修订)的要求,现将浙江圣达生物药业股份 有限公司(以下简称"公司")2025年第二季度主要经营数据披露如下: 一、报告期 ...
圣达生物: 浙江圣达生物药业股份有限公司向特定对象发行股票证券募集说明书(注册稿)
Zheng Quan Zhi Xing· 2025-05-22 10:28
Group 1 - The company Zhejiang Shengda Bio-Pharm Co., Ltd. plans to issue shares to specific investors, with the total amount of funds raised not exceeding 267.61 million yuan [1][2] - The issuance has been approved by the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][2] - The funds raised will be used for a project to produce 20,000 tons of D-isomeric ascorbic acid and its sodium salt, with a total investment of 368 million yuan [1][2] Group 2 - The issuance will involve no more than 51,356,687 shares, which is capped at 30% of the company's total share capital prior to the issuance [2][3] - The final number of shares to be issued will be determined based on the actual situation at the time of issuance [3] - Shares acquired through this issuance will be subject to a six-month lock-up period [3][4] Group 3 - The company has a plan for shareholder returns over the next three years (2023-2025), considering factors such as operational development and shareholder expectations [4] - The company will adjust the order and amount of funds allocated to projects if the actual funds raised are less than the planned investment [2][4] - The company has committed to measures to mitigate the impact of immediate return dilution on small investors [4][5] Group 4 - The company operates in the food and feed additive industry, focusing on products such as biotin and lactic acid bacteriocin [5][6] - The industry is experiencing rapid growth, but increased competition may affect profit margins [5][6] - The company has established a significant position in the market, being one of the earliest developers of biotin and biological preservatives in China [5][6]